ABBV · Full Picture

AbbVie Inc. — the full picture

Earnings window · 2026-07-13 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 87
    +45.7% revenue (realized); 3 sources (news, press_release, sec_filing); 4 forward row(s); structured_verified
    AbbVie Inc. reported second-quarter adjusted EPS of $3.65 and revenue of $16.99 billion, representing 10.2% year-over-year growth.
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 80
    -3.5% liability; 3 sources (news, press_release, sec_filing); 14 forward row(s); structured_verified
    AbbVie acquired Apogee Therapeutics for $10.9 billion.
  3. Outstanding Indebtedness · Debt, leverage & refinancingPriority 79
    -10.5% liability; 2 sources (news, sec_filing); 6 forward row(s); structured_verified
    AbbVie completed an $8.75 billion underwritten notes offering to finance a portion of its acquisition of Apogee Therapeutics.
  4. U.S. Manufacturing Investment · UnclassifiedPriority 75
    -62.9% cash; 5 forward row(s); quote_verified
    AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade as part of a voluntary agreement announced in January 2026.
  5. Operating Expense Trends · Operating expenses (SG&A)Priority 68
    -18.9% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    Specified items for the quarter ended June 30, 2026 included intangible asset amortization pre-tax of $1,689 million and change in fair value of contingent consideration pre-tax of $1,518 million.
  6. Product / Drug Pipeline Progress · Products & launchesPriority 63
    3 sources (news, press_release, sec_filing); 6 forward row(s); quote_verified
    AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months.
  7. Regulatory Approval Milestones · Regulatory action & investigationsPriority 63
    3 sources (news, press_release, sec_filing); 12 forward row(s); quote_verified
    Rinvoq sales were expected to reach around $10.2 billion in 2026 according to one report mentioning the drug's role as a significant growth driver for AbbVie.
  8. Immunology Product Demand and Expansion · UnclassifiedPriority 60
    2 sources (news, press_release); 1 forward row(s); quote_verified
    AbbVie anticipates combined Skyrizi and Rinvoq sales to surpass $31 billion in 2026.
  9. Market Demand Trends · Demand, orders & backlogPriority 58
    2 sources (news, sec_filing); 1 forward row(s); quote_verified
    Allergan Aesthetics, an AbbVie company, launched AA Signature: SKIN360 in the United States as a multimodal consultation program leveraging products including SKINVIVE by JUVÉDERM, SkinMedica HA 5 Hydra Collagen Hydrator, and BOTOX Cosmetic.
  10. Regulatory Environment · Regulatory action & investigationsPriority 58
    2 forward row(s); quote_verified
    Centers for Medicare and Medicaid Services selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028.
  11. Competition and Market Position · Competition & market sharePriority 57
    +10.2% revenue (realized); 1 forward row(s); quote_verified
    Trefis reports pivotal clinical trial data for AbbVie's hidradenitis suppurativa pipeline is expected later this year.
  12. Guidance / Outlook · Guidance & outlookPriority 57
    +1.5% revenue; 3 sources (news, press_release, sec_filing); 6 forward row(s); quote_verified
    AbbVie maintains its outlook for high-single-digit annual revenue growth through the decade.

Threads by pillar

Revenue & Demand Priority 93 · 7 threads

Costs & Margins Priority 76 · 4 threads

Capital & Balance Sheet Priority 87 · 6 threads

Strategy & Portfolio Priority 82 · 3 threads

Legal, Regulatory & Policy Priority 75 · 6 threads

Guidance & Outlook Priority 57 · 1 thread

Macro & Market Conditions Priority 57 · 1 thread

Unclassified Priority 81 · 3 threads

Expected impact by metric

metricforward netforward grossrealized
cash-53.1%+86.8%+1.8%
liability-15.2%+16.1%-3.0%
revenue+1.5%+1.5%+55.9%
operating_income——-20.6%